Skip to main content

Table 1 Descriptive Analysis of demographic and clinical data

From: Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

Parameter (N) Categories Frequency (%)
Gender (258) Female 65.1%
Male 34.9%
Comorbidities (258) Present 12.4%
Absent 87.6%
Disease duration (258) <  5 years 35.7%
5–10 years 29.4%
>  10 years 34.9%
Walking disability (258) Fully ambulatory, self-sufficient, which represents EDSS 0–3 46.8%
Ambulatory for 500 m without aid/rest which represents EDSS 4–4.5 16.3%
Ambulatory for 200 m without aid/rest which represents EDSS 5 14.0%
Intermittent or unilateral constant assistance which represents EDSS 5.5–6 12.4%
Constant bilateral assistance (canes, crutches, or braces) which represents EDSS 6.5 6.2%
restricted to wheelchair which represents EDSS 7 4.3%
Total Number of Rituximab injections (258) Once 7.8%
Twice 16.3%
3 times 14.7%
>  4 times 61.2%
Extended interval dosing (258) Yes 28.7%
No 71.3%
Relapse during the pandemic (258) Yes 16.3%
No 83.7%
Relapse management (42) Outpatient 35.7%
Inpatient 9.6%
Not treated 54.7%
Recent corticosteroid use (42) Yes 14.3%
No 85.71%
self-isolation (258) Yes 87.2%
No 12.8%
Contact with COVID-19 Patients (258) Yes 4.3%
Not Aware 95.7%
Suspected Covid-19 infection (258) Yes 9.7%
No 90.3%
Assessment of Covid-19
(RT-PCR or Imaging) (258)
Performed 8.5%
Not performed 91.5%